Please login to the form below

Not currently logged in
Email:
Password:

EMA geriatric expert group

The European Medicines Agency has established an expert group to provide advice on issues related to the elderly as part of the agency's Committee for Medicinal Products for Human Use

The European Medicines Agency (EMA) has established an expert group to provide advice on issues related to the elderly as part of the agency's Committee for Medicinal Products for Human Use (CHMP).

The geriatric group consists of nine experts in the field who will assist the CHMP in several ways, including giving input on guidelines under consultation and adding a geriatric viewpoint on discussions concerning the development, assessment or safety monitoring of medicines.

Members will meet on an ad-hoc basis, communicating by e-mail, telephone conference or web conference rather than in person.

The creation of the group is part of the EMA's geriatric medicines strategy (PDF), published in February 2011.

The strategy was developed to take into account the changing environment of modern healthcare, with an increasingly ageing population.

The implementation of the strategy was described in the EMA's 'road map' to 2015, which identifies three priority areas for the agency to focus on: addressing needs in public health; facilitating access to medicines; and making sure use of medicines is safe.

8th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics